{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-023154","form_type":"8-K","ticker":"VNDA","cik":"0001347178","company_name":"Vanda Pharmaceuticals Inc.","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.039773+00:00","generated_at":"2026-05-22T07:22:04.233128+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vanda Q1 net loss widens to $29.5M; Fanapt sales up 14% but PONVORY down 18%","bullets":["Net product sales $50.0M (+5% YoY); net loss $29.5M vs $4.1M loss a year ago.","Diluted EPS -$0.50; loss reflects $15M imsidolimab license fee and higher commercial spend.","Fanapt sales $23.5M (+14%), HETLIOZ $20.9M (+4%), PONVORY $5.6M (-18%).","Cash $340.9M; full-year guidance: revenues $210-250M, year-end cash $280-320M.","Tradipitant NDA PDUFA Dec 30, 2025; Bysanti NDA PDUFA Feb 21, 2026; imsidolimab BLA expected 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-023154","json":"https://secwatch.observer/filing/0001628280-25-023154.json","markdown":"https://secwatch.observer/filing/0001628280-25-023154.md","text":"https://secwatch.observer/filing/0001628280-25-023154.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347178/000162828025023154/0001628280-25-023154-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347178/000162828025023154/vnda-20250507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T07:22:04.233128+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}